A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.
Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with Ulcerative Colitis.
100 项与 Gale Therapeutics, Inc. 相关的临床结果
0 项与 Gale Therapeutics, Inc. 相关的专利（医药）
100 项与 Gale Therapeutics, Inc. 相关的药物交易
100 项与 Gale Therapeutics, Inc. 相关的转化医学
